When no substantial carryover effects have been existing, we analyzed data from equally phases of the crossover trial and current info from the 1st period only to be a sensitivity analysis. Carryover effects had been shown for that LSAS but not for other outcomes in this trial (VAS, HDRS-17, STAI-S), and therefore data from the 1st phase on the dem